Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(2 years from now) | |
US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(8 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9764003 | NOVO | Use of long-acting GLP-1 peptides |
Jun, 2033
(9 years from now) | |
US10888605 | NOVO | GLP-1 compositions and uses thereof |
Aug, 2038
(14 years from now) | |
US11318191 | NOVO | GLP-1 compositions and uses thereof |
Feb, 2041
(17 years from now) |
Wegovy is owned by Novo.
Wegovy contains Semaglutide.
Wegovy has a total of 5 drug patents out of which 0 drug patents have expired.
Wegovy was authorised for market use on 04 June, 2021.
Wegovy is available in solution;subcutaneous dosage forms.
Wegovy can be used as method for weight management, method for weight management according to a dose escalation schedule.
The generics of Wegovy are possible to be released after 17 February, 2041.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product (NP) | Jun 4, 2024 |
New Patient Population (NPP) | Dec 23, 2025 |
Drugs and Companies using SEMAGLUTIDE ingredient
Market Authorisation Date: 04 June, 2021
Treatment: Method for weight management according to a dose escalation schedule; Method for weight management
Dosage: SOLUTION;SUBCUTANEOUS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic